Instructions for Use

Complete Information about all
IBL Products on the Internet

STAT-8-Isoprostane ELISA

Cat.-No. : CM 500431

Size : 12 x 8

Storage : 4 °C

Enzyme immunoassay for the quantitative determination of STAT-8-Isoprostane

- For research purpose only -

IBL IMMUNO-BIOLOGICAL LABORATORIES

FLUGHAFENSTRASSE 52A, D-22335 HAMBURG PHONE: + 49- (0) 40-53 28 91-0, FAX: -11
E-MAIL: IBL@IBL-HAMBURG.COM INTERNET: HTTP://WWW.IBL-HAMBURG.COM

STAT-8-Isoprostane EIA Kit

Catalog No. CM500431

TABLE OF CONTENTS

Contents of the Kit 2

Precautions 2

Warranty and Limitation of Remedy 2

If You Have Problems 2

Storage and Stability 2

Additional Items Required 3

About this Assay 3

Introduction to Competitive EIAs 4

Pre-Assay Preparation 5

Performing the Assay 11

Calculating the Results 13

Performance Characteristics 14

Troubleshooting 15

References 15

Related Products 15

Plate Template 16

Notes 16

CONTENTS OF THE KIT

Number	Item	96 well Quantity/Size	480 wells Quantity/Size
1	STAT-8-Isoprostane Polyclonal Antiserum	1 vial/100 dtn	1 vial/500 dtn
2	STAT-8-Isoprostane AP Tracer	1 vial/100 dtn	1 vial/500 dtn
3	STAT-8-Isoprostane EIA Standard	1 vial/1 each	1 vial/1 each
4	Tris Buffer Concentrate	2 vials/10 ml	4 vials/10 ml
5	AP Wash Buffer Concentrate	1 vial/5 ml	1 vial/12.5 ml
5a	DEA Buffer	1 vial/2.5 ml	1 vial/12.5 ml
6	Mouse Anti-rabbit IgG Coated Plate	1 plate/1 each	5 plates/1 each
7	Plate Cover	1 cover/1 each	5 covers/1 each
8	*p*NPP Tablets	1 vial/5 each	1 vial/25 each
14	EIA Tracer Dye	1 vial/1 each	1 vial/1 each
15	EIA AntiserumDye	1 vial/1 each	1 vial/1 each

If any of the items listed above are damaged or missing, please contact our Customer Service department at (800) 364-9897 or (734) 971-3335. We cannot accept any returns without prior authorization.

PRECAUTIONS

WARNING: This product is not intended or approved for use in humans or veterinary animals. Reliance on this product for analyte measurements in a therapeutic setting is hazardous and may result in illness or injury.

- Please read these instructions carefully before beginning this assay.
- The reagents in this kit have been tested and formulated to work exclusively with Cayman's STAT-8-Isoprostane EIA kits. This kit may not perform as described if any reagent or procedure is replaced or modified.
- For research use only. Not for human or diagnostic use.

WARRANTY AND LIMITATION OF REMEDY

Cayman Chemical Company makes no warranty of any kind, expressed or implied, including, but not limited to, the warranties of fitness for a particular purpose and merchantability, which extends beyond the description of the chemicals on the face hereof, except that the material will meet our specifications at the time of delivery. Buyer's exclusive remedy and Cayman Chemical Company's sole liability hereunder shall be limited to refund of the purchase price of, or at Cayman Chemical Company's option, the replacement of, all material that does not meet our specifications. Cayman Chemical Company shall not be liable otherwise or for incidental or consequential damages, including, but not limited to, the costs of handling. Said refund or replacement is conditioned on Buyer giving written notice to Cayman Chemical Company within thirty (30) days after arrival of the material at its destination. Failure of Buyer to give said notice within said thirty (30) days shall constitute a waiver by Buyer of all claims hereunder with respect to said material.

IF YOU HAVE PROBLEMS

Our technical service staff may be reached by phone (800-364-9897, 734-971-3335), fax (734-971-3640), or E-Mail (techserv@caymanchem.com) Monday through Friday 8:00 AM to 6:00 PM EST. In order for our staff to assist you quickly and efficiently, please be ready to supply the lot number of the kit (found on the outside of the box).

Cayman Chemical offers an introductory course in EIA theory and practice. Please contact our Customer Service Department for more information.

STORAGE AND STABILITY

This kit will perform as specified if stored at 4°C and used before the expiration date indicated on the outside of the box.

ADDITIONAL ITEMS REQUIRED

1. A plate reader with a 405-420 nm filter.
2. An adjustable pipettor.
3. A source of "UltraPure" water. Water used to prepare all EIA reagents and buffers must be deionized and free of trace organic contaminants ("UltraPure"). Use activated carbon filter cartridges or other organic scavengers. Glass distilled water (even if double distilled), HPLC-grade water, and sterile water (for injections) are not adequate for EIA. *[NOTE: UltraPure water is available for purchase (Catalog No. 400000).]*
4. Materials used for sample preparation (see page 5).

ABOUT THIS ASSAY

Biochemistry of 8-isoprostane

The isoprostanes are a family of eicosanoids of non-enzymatic origin produced by the random oxidation of tissue phospholipids by oxygen radicals. Isoprostanes appear as artifacts in tissue and plasma samples which have undergone oxidative degradation during prolonged or improper storage. They also appear in the plasma and urine under normal conditions and are elevated by oxidative stress.

At least one of the isoprostanes, 8-isoprostane (8-*iso* $PGF_{2\alpha}$), has been shown to have biological activity. It is a potent pulmonary and renal vasoconstrictor[1] and has been implicated as a causative mediator of hepatorenal syndrome and pulmonary oxygen toxicity.[2] 8-Isoprostane has been proposed as a marker of antioxidant deficiency and oxidative stress and elevated levels have been found in heavy smokers.[3] 8-Isoprostane levels are also a relative indicator of sample integrity for lipid-containing samples such as serum, plasma, and whole cell preparations.[4] Plasma from healthy volunteers contains modest amounts of 8-isoprostane (40-100 pg/ml) that increase with the age of the test subject.[5] Normal human urinary levels range from 10-50 ng/mmol creatinine, which is an order of magnitude higher than many enzymatically derived eicosanoids.[5,6] A scheme of 8-isoprostane generation is shown in Figure 1 (see below).

Phospholipid in tissue (cell membrane) or plasma (lipoprotein)

CH_2-O-Fatty Acid
CH_2-O-Arachidonate
CH_2-O-PO_3-R^+

R = $(CH_2)_2N(CH_3)_3$

$^-O_2^\bullet$ *or* $R^\bullet$

CH_2-O-Fatty Acid
CH_2-O-Peroxy Acid
CH_2-O-PO_3-R^+

β-Cleavage → 4-hydroxy nonenal + other aldehydes

Rearrangement

CH_2-O-Fatty Acid
CH_2-O-Endoperoxide
CH_2-O-PO_3-R^+

→ malondialdehyde + 12(S)-HHTrE [12(S)-HHT]

Reduction by cellular peroxidases

CH_2-O-Fatty Acid
CH_2-O-Isoprostanes
CH_2-O-PO_3-R^+

Phospholipase A_2 → 8-Isoprostane (8-*epi* $PGF_{2\alpha}$) + other *cis*- side-chain isomers + lyso-phospholipids

Figure 1. The formation of 8-isoprostane

INTRODUCTION TO COMPETITIVE EIAs

Description of the Competitive Enzyme Immunoassay

This assay is based on the competition between 8-isoprostane and a 8-isoprostane-alkaline phosphatase conjugate (8-isoprostane tracer) for a limited number of 8-isoprostane-specific rabbit antiserum binding sites. Because the concentration of the 8-isoprostane tracer is held constant while the concentration of 8-isoprostane varies, the amount of 8-isoprostane tracer that is able to bind to the 8-isoprostane polyclonal antiserum will be inversely proportional to the concentration of 8-isoprostane in the well. This antibody-8-isoprostane complex binds to mouse monoclonal anti-rabbit IgG that has been previously attached to the well. The plate is washed to remove any unbound reagents and then *para*-nitrophenyl phosphate (*p*NPP) is added to the well. The product of this enzymatic reaction has a distinct yellow color and absorbs strongly at 412 nm. The intensity of this color, determined spectrophotometrically, is proportional to the amount of 8-isoprostane tracer bound to the well, which is inversely proportional to the amount of free 8-isoprostane present in the well during the incubation; or

$$\textbf{Absorbance} \propto \textbf{[Bound 8-Isoprostane Tracer]} \propto \textbf{1/[8-Isoprostane]}$$

A schematic of this process is shown in Figure 2 (see below).



Figure 2. Schematic of the EIA

Definition of Key Terms

Blank: background absorbance caused by *p*NPP solution. Even freshly prepared *p*NPP solution has some measurable absorbance, approximately 0.1 Absorbance Units (A.U.). The blank absorbance should be subtracted from the absorbance readings of all the other wells.

Total Activity: total enzymatic activity of the alkaline phosphatase-linked tracer. This is analogous to the specific activity of a radioactive tracer.

NSB (Non-Specific Binding): non-immunological binding of the tracer to the well. Even in the absence of specific antibody a very small amount of tracer still binds to the well; the NSB is a measure of this low binding.

B_0 (Maximum Binding): maximum amount of the tracer that the antibody can bind in the absence of free analyte.

%B/B_0 (%Bound/Maximum Bound): ratio of the absorbance of a particular sample or standard well to that of the maximum binding (B_0) well.

Standard Curve: a plot of the %B/B_0 values versus concentration of a series of wells containing various known amounts of analyte.

PRE-ASSAY PREPARATION

Water used to prepare all EIA reagents and buffers must be deionized and free of trace organic contaminants ("UltraPure"). Use activated carbon filter cartridges or other organic scavengers. Glass distilled water (even if double distilled), HPLC-grade water, and sterile water (for injections) are not adequate for EIA (Catalog No. 400000).

Buffer Preparation *(Store all buffers at 4°C)*

1. **Tris Buffer Preparation**

   Dilute the contents of one vial of Tris Buffer (vial #4) with 90 ml of UltraPure water. Be certain to rinse the vial to remove any salts that may have precipitated *[NOTE: It is normal for the concentrated buffer to contain crystalline salts after thawing. These will completely dissolve upon dilution with water.]*

2. **AP Wash Buffer Preparation**

   Dilute the contents of the vial (5 ml) of AP Wash Buffer Concentrate (vial #5) to a total volume of 750 ml with UltraPure water, or dilute the contents of the vial (12.5 ml) of AP Wash Buffer Concentrate (vial #5) to a total volume of 1,875 ml with UltraPure water.

3. **DEA Buffer Preparation**

   Dilute the contents of the vial (2.5 ml) of DEA Buffer Concentrate (vial #5a) to a total volume of 25 ml with UltraPure water, or dilute the contents of the vial (12.5 ml) of DEA Buffer Concentrate (vial #5a) to a total volume of 125 ml with UltraPure water.

Sample Preparation

This assay has been validated for a wide range of samples including urine and plasma. Proper sample storage and preparation are essential for consistent and accurate results. Please read this section thoroughly before beginning the assay.

In general, tissue culture supernatant samples may be diluted with Tris buffer and added directly to the assay well. Plasma, serum, urine, whole blood, as well as other heterogeneous mixtures such as lavage fluids and aspirates often contain contaminants which can interfere in the assay. It is best to check for interference before embarking on a large number of sample measurements. To test for interference, dilute one or two test samples to obtain at least two different dilutions of each sample between ~40 and 1,000 pg/ml (i.e., 20-80% B/B_0). If the two different dilutions of the sample show good correlation (differ by 20% or less) in the final calculated 8-isoprostane concentration, purification is not required. If you do not see good correlation of the different dilutions, purification is advised.

Cayman Chemical Company offers an 8-Isoprostane Affinity Column and Affinity Sorbent (Catalog Nos. 416358 and 416359) for simpler purification of samples. The affinity column purification procedures have been validated with plasma and urine samples. Recoveries averaged >90% with a variance of <20%. The SPE (solid phase extraction) purification methods described (see pages 8-9) were validated by a comparison of the data from EIA and gas chromatography/negative ion chemical ionization-mass spectrometry (GC/NICI-MS). GC/NICI-MS analysis was performed on samples derivatized as pentafluorobenzyl esters and *tert*-butyldimethyl-silyl ethers.[7]

General Precautions

1. All samples must be free of organic solvents prior to assay.
2. Samples should be assayed immediately after collection; samples that cannot be assayed immediately should be stored at -80°C in the presence of 0.005% BHT. Storage at -20°C is insufficient to prevent oxidative formation of 8-isoprostane.[7]

1. Lavage Fluids and Aspirates

Some lavage fluids may be assayed without any purification. Be certain to dilute the standards in the same medium as your samples. *[NOTE: If you obtain inconsistent results, SPE or immunoaffinity purification is warranted.]*

2. Urine

Urine samples give excellent correlation to GC/MS if purified by SPE and TLC (see Figure 3, below) or immunoaffinity methods prior to analysis.



Figure 3. Comparison of urine samples purified by SPE (top) and by SPE and TLC (bottom).

3. Culture Media

Culture media samples not containing any phosphates can be assayed without purification. If the estimated concentration of your samples is too low to allow dilution with Tris Buffer, be certain to dilute the EIA standards in the same medium as your samples. *[NOTE: If you obtain inconsistent results, SPE or immunoaffinity purification is warranted.]*

4. Plasma

Plasma samples should be collected in vacutainers containing sodium citrate, heparin, or EDTA. Vacutainers can also be supplemented with indomethacin to give a final concentration of at least 10 μM. Indomethacin will prevent *ex vivo* formation of eicosanoids, which have the potential to interfere with this assay (although most eicosanoids do not appear to exhibit any cross-reactivity (see page 14)).

Less than half of total plasma 8-isoprostane is present as the free acid, while the remainder is esterified in lipoproteins.[3] Direct EIA of plasma samples without hydrolysis will measure only the free 8-isoprostane fraction. Total plasma 8-isoprostane determination requires an alkaline hydrolysis prior to EIA (see page 9).

Plasma samples give excellent correlation to GC/MS if purified prior to analysis (see Figure 4, below). Analysis of plasma samples without purification may lead to inconsistent results. If inconsistent results are obtained, we recommend the immunoaffinity purification as the easiest and most convenient purification format (see Figure 5, page 8).



Figure 4. Correlation of plasma samples purified by SPE.



Figure 5. Correlation of plasma and urine samples from immunoaffinity purification.

5. **Tissue**

Tissue samples should be homogenized in 0.1 M Tris, pH 7.4, containing 1 mM EDTA and 10 μM indomethacin using a polytron type homogenizer and then processed as plasma samples. Again, most of the 8-isoprostane will be esterified in lipids, so hydrolysis must be performed in order to determine total amounts of 8-isoprostane.

SAMPLE PURIFICATION

All purifications can be checked for recovery by adding a radioactive tracer at the appropriate step. Tritiated $PGF_{2\alpha}$ can be used as a surrogate for tritiated 8-*iso* $PGF_{2\alpha}$ in the SPE purification if tritiated 8-*iso* $PGF_{2\alpha}$ is not available.

A. Determination of Free 8-Isoprostane

1. **Preparation for Affinity Sorbent/Column Purification**

Urine samples should be centrifuged briefly to remove sediment. Centrifuge plasma samples briefly and dilute 1:5 in Eicosanoid Affinity Column Buffer (0.1 M potassium phosphate, pH 7.4, containing 0.5 M NaCl and 0.05% NaN_3; this buffer may also be purchased as a 5X concentrate, Catalog No. 400220). Proceed with the purification using the 8-Isoprostane Affinity Sorbent, Column, or Purification Kit (Catalog Nos. 416359, 416358, and 516358).

2. **Preparation for SPE Purification**

a. Aliquot a known amount of sample (1 ml plasma or 1 g homogenized tissue will be used as an example) to a test tube. Add 10,000 cpm of tritium-labeled 8-*iso* $PGF_{2\alpha}$ ($[^3H]$-8-*iso* $PGF_{2\alpha}$ (Catalog No. 216350)) or $[^3H]$-$PGF_{2\alpha}$. *[NOTE: Some preparations of $[^3H]$-8-iso $PGF_{2\alpha}$ may have low specific activity. In this case, the $[^3H]$-8-iso $PGF_{2\alpha}$ may be detected in the EIA.]*

b. Add 2-4 volumes of ethanol to the sample and vortex. Allow the samples to stand at 4°C for 5 minutes, then centrifuge at 1,500 x g for 10 minutes to remove precipitated proteins. *[NOTE: Precipitation of proteins using ethanol is optional and may not be needed if samples are clean enough to flow through the SPE.]*

c. Decant the supernatant into a clean test tube.

d. Evaporate the ethanol (to <10% v/v) either by vacuum centrifugation or under a gentle stream of nitrogen (it is not necessary to completely dry the sample).

e. Adjust the pH of the sample to ~4.0 using dilute HCl or acetic acid OR 1.0 M acetate buffer or citrate buffer (pH 4.0). (Standardize the pH adjustment using the sample matrix prior to proceeding with a large number of samples; approximately 1-2 equivalents of buffer is required for most biological samples.) If the samples are cloudy or contain precipitate, either filter or centrifuge to remove the precipitate. Particulate matter in the sample may clog the SPE cartridge, resulting in loss of the sample.

f. Proceed to the Purification Protocol for the SPE cartridge (see page 9).

B. Determination of Total (free and esterified) 8-Isoprostane

1. Aliquot a known amount of sample (1 ml plasma or 1 g homogenized tissue will be used as an example) to a test tube. If SPE purification will be utilized, add 10,000 cpm of $[^3H]$-8-*iso* $PGF_{2\alpha}$ or $[^3H]$-$PGF_{2\alpha}$.
2. Add an equal volume of 15% wt/vol KOH and incubate at 40°C for 60 minutes.
3. Add 2-4 volumes of ethanol containing 0.01% BHT to the sample and vortex. Incubate at 4°C for 5 minutes, then centrifuge at 1,500 x g for 10 minutes to remove precipitated proteins. *[NOTE: Precipitation of proteins using ethanol is optional and may not be needed if samples are clean enough to flow through the SPE.]*
4. Decant the supernatant into a clean test tube.
5. Evaporate the ethanol (to <10% v/v) under a gentle stream of nitrogen (it is not necessary to completely dry the sample).
6. Continue to process the samples as described below for the appropriate technique being utilized.

a. Affinity Sorbent/Column Purification

After the ethanol has been evaporated, neutralize the sample to ~pH 7.0-7.4 by the addition of 1 M KH_2PO_4 (~3 ml). (Standardize the pH adjustment using the sample matrix prior to proceeding with a large number of samples; approximately 1-2 equivalents of KH_2PO_4 is required for most biological samples.) Add 1-2 ml of Eicosanoid Affinity Column Buffer (0.1 M potassium phosphate, pH 7.4, containing 0.5 M NaCl and 0.05% sodium azide; this buffer may also be purchased as a 5X concentrate, Catalog No. 400220). Proceed with the purification using the 8-Isoprostane Affinity Sorbent, Column, or Purification Kit (Catalog Nos. 416359, 416358, and 516358).

OR

b. SPE/TLC Purification

After the ethanol has been evaporated, acidify the sample to ~pH 4.0 by the addition of 30% acetic acid (~2-2.5 ml) or 1.0 M acetate buffer or citrate buffer (pH 4.0). (Standardize the pH adjustment using the sample matrix prior to proceeding with a large number of samples.) Proceed with the purification as described below.

Purification Protocol (SPE/TLC method)

A. Activate a C-18 SPE cartridge (Catalog No. 400020) by rinsing with 5 ml methanol and then with 5 ml UltraPure water. Do not allow the cartridge to become dry.

B. Pass the sample [either from steps A2f or B6b, or from urine samples, which have been adjusted to pH ~4.0 and spiked with 10,000 cpm of $[^3H]$-8-*iso* $PGF_{2\alpha}$ (Catalog No. 216350) or $[^3H]$-$PGF_{2\alpha}$], through the SPE cartridge. Rinse the cartridge with 5 ml UltraPure water, followed by 5 ml HPLC grade hexane (allow the cartridge to become dry after this step). Discard both the washes. Elute the 8-isoprostane with 5 ml ethyl acetate containing 1% methanol.

C. Remove 10% of the eluate for scintillation counting.*

D. Evaporate the ethyl acetate to dryness by evaporation under a stream of dry nitrogen. For plasma, serum, and most lavage fluids, skip to step H.

E. Dissolve the sample in a small amount of acetone and spot in the preadsorbent zone of a channeled 20 x 20 cm TLC plate without any fluorescent indicator (e.g., Analtech 31911, Whatman 4865-821). The preadsorbent zone of the plates will concentrate the sample into a thin line at the solvent front so there is no need for special precautions when spotting the sample. At least 1 µg of authentic 8-isoprostane (Catalog No. 16350) must be spotted on one of the edge lanes of each plate to help locate the appropriate bands in your sample. Develop the plate using chloroform/methanol/acetic acid/water (80:18:1:0.8, v/v).

F. After the solvent has traveled to the top of the plate, remove the plate from the solvent chamber and allow to dry. The band containing 8-isoprostane may be detected in one of two ways: masking all of the lanes except the one containing the authentic standard and spraying this lane with 3.5% phosphomolybdic acid, or by carefully spreading a mixture of iodine and silica gel on the 8-isoprostane lane and removing after 5 minutes.

G. Carefully scrape the band corresponding to 8-isoprostane from each sample lane onto a piece of weighing paper and transfer into a clean test tube. Elute the sample by adding 4 ml ethanol, vortexing, and then centrifuging at 1,500 x g for 10 minutes. Decant the supernatant into a clean test tube and evaporate the solvent using a stream of dry nitrogen.

H. Add 450 µl of Tris Buffer and vortex. Use this for EIA analysis. It is common for an insoluble precipitate to remain after the addition of Tris buffer; this will not affect the assay.

*If it is necessary to stop during this purification, samples may be stored in the ethyl acetate/methanol solution at -80°C.

Preparation of Assay-Specific Reagents

1. STAT-8-isoprostane Standard

Equilibrate a pipet tip in ethanol by repeatedly filling and expelling the tip with ethanol several times. Using the equilibrated pipet tip, transfer 100 µl of the STAT-8-isoprostane Standard (vial #3) into a clean test tube, then dilute with 900 µl UltraPure water. The concentration of this solution (the bulk standard) will be 30 ng/ml.

[NOTE: If assaying culture media samples that have not been diluted with Tris Buffer, culture medium should be used in place of Tris Buffer for dilution of the standard curve.]

To prepare the standard for use in EIA: Obtain 8 clean test tubes and number them #1 through #8. Aliquot 900 µl Tris Buffer to tube #1 and 500 µl Tris Buffer to tubes #2-8. Transfer 100 µl of the bulk standard (30 ng/ml) to tube #1 and mix thoroughly. Serially dilute the standard by removing 500 µl from tube #1 and placing in tube #2; mix thoroughly. Next, remove 500 µl from tube #2 and place it into tube #3; mix thoroughly. Repeat this process for tubes #4-8. These diluted standards should not be stored for more than 24 hours.

2. STAT-8-isoprostane AP Tracer

Dilute the 100 dtn STAT-8-isoprostane AP Tracer (vial #2) with 6 ml Tris Buffer or the 500 dtn STAT-8-isoprostane AP Tracer (vial #2) with 30 ml Tris Buffer. Store the diluted STAT-8-isoprostane AP Tracer at 4°C *(do not freeze!)* and use within four weeks. A 20% surplus of STAT-8-isoprostane AP Tracer has been included to account for any incidental losses.

Tracer Dye Instructions (Optional)

This dye may be added to the tracer, if desired, to aid in visualization of tracer-containing wells. Add the dye to the reconstituted tracer at a final dilution of 1:100 (add 60 µl of dye to 6 ml tracer or add 300 µl of dye to 30 ml of tracer).

3. STAT-8-isoprostane Polyclonal Antiserum

Reconstitute the 100 dtn STAT-8-isoprostane Polyclonal Antiserum (vial #1) with 6 ml Tris Buffer or the 500 dtn STAT-8-isoprostane Polyclonal Antiserum (vial #1) with 30 ml Tris Buffer. Store the reconstituted STAT-8-isoprostane Polyclonal Antiserum at 4°C. It will be stable for at least four weeks. A 20% surplus of STAT-8-isoprostane Polyclonal Antiserum has been included to account for any incidental losses.

Antiserum Dye Instructions (Optional)

This dye may be added to the antiserum, if desired, to aid in visualization of antiserum-containing wells. Add the dye to the reconstituted antiserum at a final dilution of 1:100 (add 60 µl of dye to 6 ml antiserum or add 300 µl of dye to 30 ml of antiserum).

PERFORMING THE ASSAY

Plate Set Up

The 96 well plate(s) included with this kit is supplied ready to use. It is not necessary to rinse the plate(s) prior to adding the reagents. *[NOTE: If you do not need to use all the strips at once, place the unused strips back in the plate packet and store at 2-4°C. Be sure the packet is sealed with the desiccant inside.]*

Each plate or set of strips must contain a minimum of two blanks (Blk), two non-specific binding wells (NSB), two maximum binding wells (B_0), and an eight point standard curve run in duplicate. *[NOTE: Each assay must contain this minimum configuration in order to ensure accurate and reproducible results.]* Each sample should be assayed at two dilutions and each dilution should be assayed in duplicate. For statistical purposes, we recommend assaying samples in triplicate.

A suggested plate format is shown in Figure 6, (see below). The user may vary the location and type of wells present as necessary for each particular experiment. The plate format provided below has been designed to allow for easy data analysis using a convenient spreadsheet offered by Cayman Chemical (see page 13, Calculating the Results for more details). We suggest you record the contents of each well on the template sheet provided (see page 16).

Full Plate Format

	1	2	3	4	5	6	7	8	9	10	11	12
A	Blk	S1	S1	1	1	1	9	9	9	17	17	17
B	Blk	S2	S2	2	2	2	10	10	10	18	18	18
C	NSB	S3	S3	3	3	3	11	11	11	19	19	19
D	NSB	S4	S4	4	4	4	12	12	12	20	20	20
E	B_0	S5	S5	5	5	5	13	13	13	21	21	21
F	B_0	S6	S6	6	6	6	14	14	14	22	22	22
G	B_0	S7	S7	7	7	7	15	15	15	23	23	23
H	TA	S8	S8	8	8	8	16	16	16	24	24	24

Blk - Blank
TA - Total Activity
NSB - Non-Specific Binding
B_0 - Maximum Binding
S1-S8 - Standards 1-8
1-24 - Samples

Figure 6. Sample plate format

Pipet the Reagents

PIPETTING HINTS

- **Use different tips to pipet the buffer, standard, sample, tracer, and antibody.**
- **Before pipetting each reagent, equilibrate the pipet tip in that reagent (i.e., slowly fill the tip and gently expel the contents, repeat several times).**
- **Do not expose the pipet tip to the reagent(s) already in the well.**

1. **Tris Buffer**

   Add 100 µl Tris Buffer to Non-Specific Binding (NSB) wells. Add 50 µl Tris Buffer to Maximum Binding (B_0) wells. If culture medium was used to dilute the standard curve, substitute 50 µl of culture medium for Tris Buffer in the NSB and B_0 wells (i.e., add 50 µl culture medium to NSB and B_0 wells and 50 µl Tris Buffer to NSB wells).

2. **STAT-8-isoprostane Standard**

   Add 50 µl from tube #8 to both of the lowest standard wells (S8). Add 50 µl from tube #7 to each of the next two standard wells (S7). Continue with this procedure until all the standards are aliquoted. The same pipet tip should be used to aliquot all the standards. Before pipetting each standard, be sure to equilibrate the pipet tip in that standard.

3. **Samples**

   Add 50 µl of sample per well. Each sample should be assayed at a minimum of two dilutions. Each dilution should be assayed in duplicate (triplicate recommended).

4. **STAT-8-isoprostane AP Tracer**

   Add 50 µl to each well *except* the Total Activity (TA) and the Blank (Blk) wells.

5. **STAT-8-isoprostane Polyclonal Antiserum**

   Add 50 µl to each well *except* the Total Activity (TA), the Non-Specific Binding (NSB), and the Blank (Blk) wells.

Well	Tris Buffer	Standard/Sample	Tracer	Antiserum
Blk	-	-	-	-
TA	-	-	5 µl (at devl. step)	-
NSB	100 µl	-	50 µl	-
B_0	50 µl	-	50 µl	50 µl
Std/Sample	-	50 µl	50 µl	50 µl

Table 1: Quick Reference Pipetting Summary

Incubate the Plate

Cover each plate with plastic film (item #7) and incubate for 1 hour at room temperature. We recommend that the plate be incubated on an orbital shaker.

Develop the Plate

When ready to develop the plate(s), reconstitute 5 *p*NPP tablets in 25 ml DEA buffer (25 ml is sufficient to develop 100 wells). Reconstituted *p*NPP is not stable, so we recommend that you store the reconstituted *p*NPP for no more than 24 hours. If the entire plate is not used at once, dissolve just enough *p*NPP for the number of wells used.

Empty the wells and rinse five times with AP Wash Buffer. Add 200 µl of *p*NPP solution to each well and 5 µl of tracer to the Total Activity wells. Cover the plate with plastic film.

Optimum development is obtained by using an orbital shaker equipped with a large, flat cover to allow the plate(s) to develop in the dark. This assay typically develops (i.e., B_0 wells equal 0.3 A.U. (blank subtracted)) in 60-90 minutes.

Read the Plate

Read the plate(s) at a wavelength between 405-420 nm. Before reading each plate, wipe the bottom of the plate with a clean tissue to remove finger prints, dirt, etc., as smudges on the bottom of the plate can significantly alter absorbance readings. Be certain that the *p*NPP solution has not splashed up on the plate cover as any loss of *p*NPP solution will affect the absorbance readings. If it did, use a pipet to remove the *p*NPP solution from the cover and place into the well.

The plate may be checked periodically until the B_0 wells have reached a minimum of 0.3 A.U. (blank subtracted). The plate should be read when the absorbance of the B_0 wells is in the range of 0.3-0.8 A.U. (blank subtracted).

CALCULATING THE RESULTS

It is usually more convenient to calculate the assay results by computer; most plate readers come with data reduction software, or a spreadsheet program can be used (4-parameter logistic or log-logit curve fit). *[Cayman Chemical has a computer spreadsheet available for data anaylsis. Please contact Technical Service or visit our website (www.caymanchem.com/analysis/eia) for more information or to obtain a free copy of this convenient data analysis tool.]* If the results need to be calculated manually, the procedure is as follows:

[NOTE: If the plate reader has not subtracted the absorbance readings of the blank wells from the absorbance readings of the rest of the plate, be sure to do that now.]

1. Average the absorbance readings from the NSB wells.
2. Average the absorbance readings from the B_0 wells.
3. Subtract the NSB average from the B_0 average. This is the corrected B_0 or corrected maximum binding.
4. Calculate the $\%B/B_0$ (% Sample or Standard Bound/Maximum Bound) for the remaining wells. To do this, subtract the average NSB absorbance from the S1 absorbance and divide by the corrected B_0 (from Step 3). Multiply by 100 to obtain $\%B/B_0$. Repeat for S2-S8 and all sample wells.
5. The total activity values are not used in the standard curve calculations. Rather, they are used as a diagnostic tool; the corrected B_0 divided by the actual TA (10X measured absorbance) will give the % Bound. This value should closely approximate the % Bound that can be calculated from the sample data (see page 14). Erratic absorbance values and a low (or no) % Bound could indicate the presence of organic solvents in the buffer or other technical problems (see page 15 for Troubleshooting).

Plotting the Standard Curve

Plot $\%B/B_0$ for standards S1-S8 versus 8-*iso* concentration (usually in pg/ml) on semi-log paper.

Determining the Concentration of your Samples

Calculate the $\%B/B_0$ value for each sample. Determine the concentration of each sample by identifying the $\%B/B_0$ on the standard curve and reading the corresponding values on the x-axis. *[NOTE: Remember to account for any dilutions to the sample prior to the addition to the well.]* $\%B/B_0$ values greater than 80% and less than 20% should be re-assayed as they generally fall out of the linear range of the standard curve.

Calculations

$$\text{Recovery Factor} = \frac{10 \times \text{cpm of sample}}{[^3\text{H}]\text{-8-}iso\ \text{PGF}_{2\alpha}\ \text{added to sample (cpm)}}$$

$$\text{8-Isoprostane (pg) in purified sample} = \left[\frac{\text{Value from EIA (pg/ml)}}{\text{Recovery Factor}}\right] \times 0.5\ \text{ml}^* - \text{added } [^3\text{H}]\text{-8-}iso\ \text{PGF}_{2\alpha}\ \text{(pg)}$$

$$\text{Total 8-Isoprostane in sample (pg/ml)} = \frac{\text{8-Isoprostane (pg) in purified sample}}{\text{Volume of sample used for purification (ml)}}$$

*Volume of reconstituted sample after purification; adjust this number accordingly if a different volume of Tris buffer was used to reconstitute the sample after purification.

PERFORMANCE CHARACTERISTICS

Precision

The intra- and interassay CV's have been determined at multiple points on the standard curve. These data are summarized in the graph below.

Specificity

Compound	Cross-reactivity
8-Isoprostane	100%
8-*iso* Prostaglandin $F_{3\alpha}$	20.55%
2,3-dinor-8-*iso* Prostaglandin $F_{2\alpha}$	4.00%
8-*iso* Prostaglandin E_2	1.84%
2,3-dinor-8-*iso* Prostaglandin $F_{1\alpha}$	1.70%
8-*iso* Prostaglandin E_1	1.56%
Prostaglandin $F_{1\alpha}$	0.71%
Prostaglandin $F_{3\alpha}$	0.66%
Prostaglandin E_1	0.39%
Prostaglandin D_2	0.16%
6-keto Prostaglandin $F_{1\alpha}$	0.14%
Prostaglandin $F_{2\alpha}$	0.14%
2,3-dinor-6-keto Prostaglandin $F_{1\alpha}$	0.09%
8-*iso* Prostaglandin $F_{1\beta}$	0.08%
Thromboxane B_2	0.08%
11-dehydro Thromboxane B_2	0.07%
11β-Prostaglandin $F_{2\alpha}$	0.03%
Prostaglandin E_2	0.02%
8-*iso*-15(R)-Prostaglandin $F_{2\alpha}$	0.02%
8,12-*epi* $iPF_{2\alpha}$ III	0.01%
$iPF_{2\alpha}$ VI	<0.01%
8,12-*epi* $iPF_{2\alpha}$ VI	<0.01%
13,14-dihydro-15-keto Prostaglandin $F_{2\alpha}$	<0.01%
Tetranor PGEM	<0.01%
Tetranor PGFM	<0.01%

Sample Data

The standard curve presented here is an example of the data typically produced with this kit; however, your results will not be identical to these. You **must** run a new standard curve - do not use this one to determine the values of your samples. Depending on the development conditions and the purity of the water used, your results could differ substantially from the data presented below. *[NOTE: Raw data is reported in milli-Absorbance Units.]*

	Raw Data		Average	Corrected
Total Activity	2,185	2,213	2,200	
NSB	0	0	0	
B_0	827	841	844	844
	849	859		

Standard Curve

Dose (pg/ml)	Raw Data		Corrected		$\%B/B_0$	
3,000	128	127	128	127	15.2	15.1
1,500	186	194	186	194	22.0	22.9
750	223	233	223	233	26.4	27.6
375	299	309	299	309	35.5	36.6
187.5	408	401	408	401	48.3	47.5
93.8	557	557	557	557	66.0	66.0
46.9	683	380	683	380	80.9	80.6
23.4	789	791	789	791	93.5	93.7



50% B/B_0 - 180 pg/ml
Detection Limit (80% B/B_0) - 45 pg/ml

TROUBLESHOOTING

Problem: Erratic values; dispersion of duplicates.
Causes: Trace organic contaminants in the water source; replace activated carbon filter or change source of UltraPure water. *-or-* Poor pipetting/technique.

Problem: High NSB (>0.035).
Causes: Poor washing. *-or-* Exposure of NSB wells to specific antiserum.

Problem: Very low B_0.
Causes: Contamination of water with organic solvents, phosphates used in sample matrix. *-or-* Plate requires additional development time. *-or-* Dilution error in preparing reagents.

Problem: Low sensitivity (shift in dose response curve).
Cause: Standard is degraded.

Problem: Analyses of two dilutions of a biological sample do not agree (i.e., more than 20% difference).
Cause: Interfering substances are present. Sample must be purified prior to analysis by EIA.[8]

Problem: Only Total Activity (TA) wells develop.
Cause: Trace organic contaminants in the water source; replace activated carbon filter or change source of UltraPure water.

REFERENCES

1. Banerjee, M., Kang, K.H., Morrow, J.D., *et al.* Effects of a novel prostaglandin, 8-*epi*-$PGF_{2\alpha}$, in rabbit lung *in situ. Am. J. Physiol.* **263**, H660-H663 (1992).
2. Vacchiano, C.A. and Tempel, G.E. Role of nonenzymatically generated prostanoid, 8-*iso*-PGF_2, in pulmonary oxygen toxicity. *J. Appl. Physiol.* **77**, 2912-2917 (1994).
3. Morrow, J.D., Frei, B., Longmire, A.W., *et al.* Increase in circulating products of lipid peroxidation (F_2-isoprostanes) in smokers. *N. Engl. J. Med.* **332**, 1198-1203 (1995).
4. Morrow, J.D., Hill, K.E., Burk, R.F., *et al.* A series of prostaglandin F_2-like compounds are produced *in vivo* in humans by a non-cyclo-oxygenase, free radical-catalyzed mechanism. *Proc. Natl. Acad. Sci. USA* **87**, 9383-9387 (1990).
5. Wang, Z., Ciabattoni, G., Créminon, C., *et al.* Immunological characterization of urinary 8-*epi*-prostaglandin $F_{2\alpha}$ excretion in man. *J. Pharmacol. Exp. Ther.* **275**, 94-100 (1995).
6. Reilly, M.P., Barry, P., Lawson, J.A., *et al.* Urinary 8-*epi* $PGF_{2\alpha}$: An index of oxidant stress *in vivo. Fibrinolysis & Proteolysis* **11**, 81-84 (1997).
7. Morrow, J.D., Harris, T.M., and Roberts, L.J., II Noncyclooxygenase oxidative formation of a series of novel prostaglandins: Analytical ramifications for measurement of eicosanoids. *Anal. Biochem.* **184**, 1-10 (1990).
8. Maxey, K.M., Maddipati, K.R., and Birkmeier, J. Interference in enzyme immunoassays. *J. Clin. Immunoassay* **15**, 116-120 (1992).

RELATED PRODUCTS

8-*iso* Prostaglandin $F_{2\alpha}$ - Cat. No. 16350 • [^{3}H]-8-*iso* Prostaglandin $F_{2\alpha}$ - Cat. No. 216350 • UltraPure Water - Cat. No. 400000 • SPE Cartridges - Cat. No. 400020 • 8-Isoprostane Affinity Column - Cat. No. 416358 • 8-Isoprostane Affinity Sorbent - Cat. No. 416359 • STAT-8-Isoprostane EIA Kit (Solid Plate) - Cat. No. 500431.1 • 8-Isoprostane EIA Kit - Cat. No. 516351 • 8-Isoprostane EIA Kit (Solid Plate) - Cat. No. 516351.1 • 8-Isoprostane Affinity Purification Kit - Cat. No. 516358

PLATE TEMPLATE

	1	2	3	4	5	6	7	8	9	10	11	12
A												
B												
C												
D												
E												
F												
G												
H												

NOTES

This document is copyrighted. All rights are reserved. This document may not, in whole or part, be copied, photocopied, reproduced, translated, or reduced to any electronic medium or machine-readable form without prior consent, in writing, from Cayman Chemical Company.

©10/09/2003, Cayman Chemical Company, Ann Arbor, MI, All rights reserved. Printed in U.S.A.